ArticlePloS one2025
Identification of plasma proteins associated with seizures in epilepsy: A consensus machine learning approach.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic Studies in Absence Epilepsy: A Systematic Review of Methodological Diversity and Implications for Data Interpretation.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood-based biomarkers in epilepsy could constitute important research tools advancing neurobiological understanding and valuable clinical tools for better diagnosis and follow-up. An interesting question is whether biomarker patterns could contribute additional understanding compared to individual marker values. We analyzed OLINK proteomics data from a large epilepsy cohort in which we have previously found four differentially expressed proteins (CDH15, PAEP, LTBP3, PHOSPHO1). Using two machine-learning techniques, we identified ten consensus candidate protein biomarkers (CDH15, PAEP, LTBP3, PHOSPHO1, NEFL, SFRP1, TDGF1, DUSP3, WWP2 and DSG3) that contributed to the classification of patients as being seizure-free or not. Six out of the ten consensus proteins were identified as differentially expressed in our previous study (although NEFL and TDGF1 not significantly so after multiple testing correction). The remaining four consensus proteins were newly identified by machine learning and were chosen for detailed analysis. In comparison to the four significantly differentially expressed proteins (CDH15, PAEP, LTBP3, PHOSPHO1), the newly identified consensus proteins (SFRP1, DSG3, DUSP3, and WWP2) and in particular a combination of all eight proteins, outperformed individual proteins in identifying individuals with recent seizures, highlighting the potential of multi-protein profiles. These findings emphasize the need for integrative bioinformatic approaches in epilepsy research and underscore the role of neuroinflammation and immune pathways in epileptogenesis. Our results support the applicability of plasma protein profiling for developing future blood-based tests for epilepsy seizure prediction, diagnosis, and treatment. Further validations in independent cohorts are required to establish these candidate biomarkers in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.